Trump’s Order on Gender-Affirming Care Escalates Reversal of Trans Rights

President Donald Trump ratcheted up his administration’s reversal of transgender rights on Tuesday with an executive order that seeks to intervene in parents’ medical decisions by prohibiting government-funded insurance coverage of puberty blockers or surgery for people under 19. Trump’s order, titled “Protecting Children From Chemical and Surgical Mutilation,” is certain to face legal challenges…

Read More

The Quiet Collapse of America’s Reproductive Health Safety Net

In late October, Maine Family Planning announced three rural clinics in northern Maine would close by month’s end. These primary care and reproductive health clinics served about 800 patients, many uninsured or on Medicaid. “People don’t realize how much these clinics hold together the local health system until they’re gone,” said George Hill, the group’s…

Read More

Sen. Ron Wyden Seeks Answers on RFK Jr.’s Purge of FOIA Staff

The Department of Health and Human Services’ mass dismissals of workers who release government records “raise grave transparency, accountability, and privacy concerns,” Oregon Sen. Ron Wyden said Thursday. In a May 8 letter to HHS Secretary Robert F. Kennedy Jr. provided exclusively to KFF Health News, Wyden, the top Democrat on the powerful Senate Finance…

Read More

Sarepta’s Future in Gene Therapy Remains Clouded, But Data From Partner Hansa Is a Bright Spot

Hansa Biopharma has encouraging early clinical results showing its drug imlifidase, used as a pretreatment, enabled Duchenne muscular dystrophy patients to receive the gene therapy Elevidys. Sarepta is searching for ways to mitigate excessive immune responses to Elevidys that can lead to serious and potentially fatal liver injury. The post Sarepta’s Future in Gene Therapy…

Read More

Beam’s Base-Editing Sickle Cell Therapy Shows Early Promise, But a Fatality Overshadows Results

The death wasn’t due to Beam Therapeutics’ sickle cell disease therapy, BEAM-101, but was instead attributed to the preconditioning treatment needed before the genetic medicine is infused. A different Beam program in preclinical development could avoid the need for toxic preconditioning; data from both programs will be presented during the upcoming American Society of Hematology…

Read More